I can't believe that after a run-up like we've seen last week that there is no mention of ENDV on SI. We ended the week up a few hundred percent and I as read it have a lot more to go.
The volume had not really increased much over the week and they will be presenting their data at a conference tomorrow (Tues March 7th) and at a Cardiology conference on March 13th. In my estimation, the run-up should see some profit taking from some long-term holders but then the run should continue to the end of the day in anticipation of tomorrow's meeting.
The two products that are in the pipeline could potentially eliminate the vast majority of cardiac bypasses performed in the US. The market is a 1-2 billion dollar market and ENDV themselves estimate 200-500 million in revenue by 2002 and 2005, respectively. One of their products is purported to decrease the restenosis (failure) rate of angioplasties to low single digits where it is 40% at present.
These two products sound great... we'll see what the company has to say tomorrow.... but come on... you gotta notice this puppy.